AMD Drug's Phase I Results To Be Presented At AAO | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Wednesday, October 29, 2008

Email

Comments

Ophthalmology Times

A biotechnology company will be presenting its ASaP phase I clinical data for its leading drug candidate (POT-4, Potentia Pharmaceuticals) during Retina Subspecialty Day at the annual meeting of the American Academy of Ophthalmology (AAO) in Atlanta Nov. 7.

Retina Products and Equipment »

Which type of cataract is associated with an increased risk of capsular rupture during surgery?
1. posterior polar
2. sutural
3. anterior subcapsular
4. posterior subcapsular
Check The Answer

3nethra classic Ophthalmic Imaging Device
The 3nethra classic is a compact, ... view product
Volk iNview
iPhone Fundus Camera The Volk iNview ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us